The federal government invited the pharmaceutical and medical technology industries to the event on Wednesday Chancelleryto advise on better medical supplies and more attractive site conditions. Representatives of companies and associations as well as several federal ministries are expected to attend the meeting with the Head of the Chancellor, Thorsten Frei (CDU). This meeting is intended to be the beginning of a pharmaceutical and medical technology strategy.
The pharmaceutical industry is one of the few sectors in Germany that is experiencing growth, but there are always bottlenecks in supply – for example fever juice, painkillers and diabetes medicines or antibiotics. Germany relies heavily on China and India for many resources. The pharmaceutical industry also blamed cost pressures on politicians for the fact that manufacturers in Germany had withdrawn from penicillin production. Due to current price regulations for many medicines in Germany, companies cannot simply pass on increased costs to customers by raising prices.
The industry sees huge savings potential
The Federal Association of German Industry (BDI) welcomed the plan for a holistic view on medicines and Medical technology. “The financial stability of our health system is under enormous pressure,” said the head of the department responsible, Rabea Knorr. It is now more important than ever to harness the innovative power of the healthcare industry in a targeted manner. According to a study, new technologies and processes could save up to 50 billion euros per year in the medium term and at the same time improve services.
Specifically, he wanted to do it Federal Government A spokesperson announced that measures are being developed to improve the supply situation and market conditions for the pharmaceutical and medical technology industry in Germany. This launch will be followed by an inter-departmental dialogue process led by the Ministry of Health. The aim is to unify formats that have existed for many years – pharmaceutical strategy and pharmaceutical dialogue.
Warning of higher drug prices
However, the framework conditions also bear in mind that higher drug prices impact the finances of statutory health insurance companies. The coalition also wants to avoid increasing contributions. The Allgemeine Ortskrankenkassen (AOK) has warned previously that “the highly profitable pharmaceutical industry is being excluded from all efficiency efforts in the German healthcare system”.
© dpa-infocom, dpa:251112-930-280535/1
